Lenograstim is a recombinant granulocyte colony-stimulating factor which functions as an immunostimulator. It is developed by Chugai Pharmaceuticals under the brand name Granocyte.
References
"USAN Council. List No. 340. New names. Lenograstim". Clin. Pharmacol. Ther. 52 (1): 112–113. July 1992. doi:10.1038/clpt.1992.117. PMID 1284891. S2CID 221603616. /wiki/Doi_(identifier) ↩
Amadori S, Suciu S, Jehn U, Stasi R, Thomas X, Marie JP, Muus P, Lefrère F, Berneman Z, Fillet G, Denzlinger C, Willemze R, Leoni P, Leone G, Casini M, Ricciuti F, Vignetti M, Beeldens F, Mandelli F, De Witte T (July 2005). "Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study". Blood. 106 (1): 27–34. doi:10.1182/blood-2004-09-3728. PMC 1895135. PMID 15761020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895135 ↩